Immatics
IMTX
7.45
-0.05
-0.67%
Immatics
US · IMTX
#3173 by market cap
Listed 2018
7.45
-0.05
-0.67%
Live - 5344 symbols - heartbeat 273s ago
· 2026-10-08 05:54
Pre-market
7.40
-0.67%
After-hours
7.88
+5.77%
Overnight
7.46
+0.13%
- Market cap
- 1.11B
- P/E (TTM)i
- -4.19
- P/Bi
- 2.49
- EPSi
- -1.80
- Div yieldi
- 0.00%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on IMTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.59, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -69.03% YoY
Margins
- Operating margin
- -377.11%
- Net margin
- -407.01%
Key ratios & quality
- Altman Z-Scorei
- 6.59
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.77M | 18.45M | 31.25M | 34.76M | 172.83M | 54.00M | 155.84M | 48.27M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.67M | 11.76M | 34.19M | 33.81M | 36.12M | 38.20M | 46.45M | 51.18M |
| Research & development | 33.97M | 40.09M | 67.09M | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M |
| Operating profit | -34.41M | -33.01M | -69.72M | -86.29M | 29.95M | -101.73M | -38.62M | -182.02M |
| Pretax profit | -32.36M | -32.49M | -211.84M | -93.34M | 42.04M | -96.99M | 21.35M | -198.44M |
| Tax | 0 | 0 | 0 | 0 | 14.33M | -2.35M | 6.13M | -1.99M |
| Net profit | -32.36M | -32.49M | -211.84M | -93.34M | 27.70M | -94.65M | 15.22M | -196.45M |
| Basic EPS | 0 | -1 | -4 | -1 | 0 | -1 | 0 | -2 |
| Diluted EPS | -0.50 | -0.50 | -4.40 | -1.48 | 0.40 | -1.18 | 0.14 | -1.61 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 18.58M | 4.74M | 5.19M | 19.76M | 7.61M | 9.14M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.07M | 12.78M | 12.67M | 13.66M | 14.51M | 13.94M |
| Research & development | 41.91M | 45.11M | 47.18M | 49.64M | 59.19M | 62.41M |
| Operating profit | -35.37M | -53.13M | -54.63M | -38.88M | -66.06M | -67.20M |
| Pretax profit | -40.85M | -71.35M | -50.67M | -35.56M | -57.76M | -62.77M |
| Tax | -994.00K | -1.00M | -127.00K | 134.00K | 52.00K | -274.00K |
| Net profit | -39.86M | -70.35M | -50.55M | -35.70M | -57.81M | -62.49M |
| Basic EPS | 0 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.33 | -0.58 | -0.42 | -0.29 | -0.43 | -0.46 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | -- | 124.00M | 238.99M | 152.21M | 377.15M | 449.37M | 629.56M | 504.01M |
| Cash & ST investments | -- | 119.38M | 231.98M | 145.12M | 362.21M | 425.90M | 604.45M | 469.34M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 134.28M | 254.65M | 174.65M | 407.82M | 509.97M | 696.15M | 562.34M |
| Total current liabilities | -- | 69.30M | 77.48M | 95.15M | 106.45M | 156.55M | 67.99M | 43.01M |
| Short-term debt | -- | 1.41M | 1.88M | 2.71M | 2.16M | 2.60M | 2.85M | 2.76M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | -- | 175,112,000.00 | 167,259,000.00 | 150,583,000.00 | 204,467,000.00 | 292,347,000.00 | 121,304,000.00 | 78,238,000.00 |
| Total equity | -- | -40.84M | 87.39M | 24.06M | 203.35M | 217.62M | 574.84M | 484.10M |
| Retained earnings | -- | -233.19M | -444.48M | -537.81M | -510.11M | -604.76M | -589.54M | -785.99M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 573.56M | 503.94M | 458.02M | 504.01M | 484.84M | 429.19M |
| Cash & ST investments | 543.76M | 478.19M | 430.84M | 469.34M | 453.57M | 393.35M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 641.69M | 567.30M | 518.56M | 562.34M | 543.26M | 485.74M |
| Total current liabilities | 55.77M | 57.25M | 62.26M | 43.01M | 55.25M | 56.95M |
| Short-term debt | 3.05M | 3.00M | 2.88M | 2.76M | 2.61M | 2.67M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 105,086,000.00 | 102,728,000.00 | 101,878,000.00 | 78,238,000.00 | 87,463,000.00 | 86,110,000.00 |
| Total equity | 536.61M | 464.57M | 416.68M | 484.10M | 455.80M | 399.63M |
| Retained earnings | -629.40M | -699.75M | -750.29M | -785.99M | -843.80M | -906.29M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 20.68M | 70.97M | -80.70M | -84.75M | 100.13M | 18.23M | -158.03M | -176.63M |
| Depreciation & amortization | 2.18M | 3.86M | 4.42M | 5.26M | 6.97M | 7.23M | 12.23M | 12.40M |
| Free cash flow | 20.18M | 68.73M | -88.22M | -90.40M | 93.92M | -12.73M | -174.51M | -183.43M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 23.65M | 0 | 217.92M | 94.00K | 134.48M | 90.40M | 343.01M | 107.31M |
| Ending cash balance | 39.37M | 103.35M | 207.53M | 132.99M | 148.52M | 218.47M | 236.75M | 345.92M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -34.21M | -39.06M | -44.70M | -58.67M | -42.04M | -60.46M |
| Depreciation & amortization | 3.14M | 3.03M | 3.07M | 3.17M | 2.78M | 3.00M |
| Free cash flow | -37.34M | -40.61M | -45.79M | -59.69M | -42.81M | -61.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 9.00K | 4.00K | 107.30M | 22.27M | 57.00K |
| Ending cash balance | 242.84M | 256.64M | 334.92M | 345.92M | 301.33M | 232.46M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -734.15 | -145.47 | 31.63 | -44.26 | 3.80 | -37.10 |
| ROA %i | -- | -23.51 | -117.79 | -43.48 | 12.88 | -21.14 | 2.52 | -31.22 |
| ROIC %i | -- | -- | -639.41 | -128.71 | 27.69 | -46.99 | -0.47 | -38.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- | -222.46 | -44.27 |
| EBIT margin %i | -857.80 | -175.17 | -733.78 | -266.86 | 24.92 | -178.09 | 14.27 | -409.17 |
| FCF / sales %i | 535.20 | 372.56 | -- | -- | 54.34 | -- | -- | -- |
| Current ratioi | -- | 1.79 | 3.08 | 1.60 | 3.54 | 2.87 | 9.26 | 11.72 |
| Quick ratioi | -- | 1.76 | 3.03 | 1.55 | 3.41 | 2.76 | 8.99 | 11.07 |
| Debt / assetsi | -- | 2.41 | 2.43 | 5.64 | 3.57 | 3.02 | 2.33 | 2.78 |
| LT debt / equityi | -- | -- | 4.93 | 29.68 | 6.10 | 5.88 | 2.32 | 2.66 |
| Interest coveragei | -2,021.19 | -190.10 | -793.52 | -163.90 | 41.50 | -115.72 | 25.09 | -208.76 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 109.70 | 110.81 | 19.99 | 64.89 | -34.64 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | 10.97 | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -4.78 | -17.54 | -28.97 | -37.10 | -43.21 | -47.80 |
| ROA %i | -3.46 | -12.52 | -21.13 | -31.22 | -36.19 | -39.23 |
| ROIC %i | -8.40 | -20.61 | -31.54 | -38.97 | -44.59 | -49.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -11.68 | -54.04 | -139.98 | -409.17 | -574.97 | -493.71 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 10.28 | 8.80 | 7.36 | 11.72 | 8.78 | 7.54 |
| Quick ratioi | 9.87 | 8.40 | 6.99 | 11.07 | 8.30 | 7.02 |
| Debt / assetsi | 2.87 | 3.02 | 3.16 | 2.78 | 2.78 | 3.01 |
| LT debt / equityi | 2.86 | 3.04 | 3.24 | 2.66 | 2.74 | 2.99 |
| Interest coveragei | -17.90 | -73.33 | -124.11 | -208.76 | -235.91 | -237.21 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of PRAME-directed immunotherapies that harness the power of T cells for100.00%
Quote time 2026-10-08 05:54:03 · For reference only, not investment advice and not tailored to your situation.